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ABSTRACT
Cytidine deaminase (CDA) is a determinant of in vivo gemcitabine
elimination kinetics and cellular toxicity. The impact of CDA activity
in pancreatic ductal adenocarcinoma (PDAC) cell lines has not been
elucidated. We hypothesized that CDA regulates gemcitabine flux
through its inactivation and activation pathways in PDAC cell lines.
Three PDAC cell lines (BxPC-3, MIA PaCa-2, and PANC-1) were
incubated with 10 or 100mMgemcitabine for 60minutes or 24 hours,
with or without tetrahydrouridine, a CDA inhibitor. Extracellular
inactive gemcitabine metabolite (dFdU) and intracellular active
metabolite (dFdCTP) were quantified with liquid chromatography
tandem mass spectrometry. Cellular expression of CDA was
assessed with real-time PCR and Western blot. Gemcitabine
conversion to dFdU was extensive in BxPC-3 and low in MIA
PaCa-2 and PANC-1, in accordance with their respective CDA
expression levels. CDA inhibition was associated with low or
undetectable dFdU in all three cell lines. After 24 hours gemcitabine
incubation, dFdCTP was highest in MIA PaCa-2 and lowest in
BxPC-3. CDA inhibition resulted in a profound dFdCTP increase in
BxPC-3 but not in MIA PaCa-2 or PANC-1. dFdCTP concentrations
were not higher after exposure to 100 versus 10 mM gemcitabine
when CDA activities were low (MIA PaCa-2 and PANC-1) or inhibited
(BxPC-3). The results suggest a regulatory role of CDA for gemci-
tabine activation in PDAC cells but within limits related to the
capacity in the activation pathway in the cell lines.
SIGNIFICANCE STATEMENT
The importance of cytidine deaminase (CDA) for cellular gemci-
tabine toxicity, linking a lower activity to higher toxicity, is well
described. An underlying assumption is that CDA, by inactivating
gemcitabine, limits the amount available for the intracellular
activation pathway. Our study is the first to illustrate this
regulatory role of CDA in pancreatic ductal adenocarcinoma cell
lines by quantifying intracellular and extracellular gemcitabine
metabolite concentrations.
Introduction
Gemcitabine (29,29-difluoro-29-deoxycytidine [dFdC]) is a nucleoside
analog used either alone or in combination with other cytostatic agents
for treatment of inoperable pancreatic ductal adenocarcinoma (PDAC)
and several other human cancers (https://www.legemiddelsok.no/).
Following intracellular uptake, mainly by transmembrane equilibrative
(hENT) and concentrative nucleoside transporter proteins (Wong et al.,
2009), gemcitabine undergoes a stepwise phosphorylation process.
Deoxycytidine kinase (dCK) catalyses the initial phosphorylation to
gemcitabine monophosphate (dFdCMP) and is considered to be the rate-
limiting step in the activation pathway (Wong et al., 2009). The main
active metabolite is gemcitabine triphosphate (dFdCTP), which inhibits
DNA replication. In tumor specimens from PDAC patients, high
expression of hENT1 and dCK have been shown to favor the outcome
of gemcitabine treatment (Maréchal et al., 2012).
Cytidine deaminase (CDA) catalyses the inactivation of gemcitabine
to 29,29-difluoro-29-deoxyuridine (dFdU) (Gusella et al., 2011; Simon
et al., 2015; Cohen et al., 2019). CDA expression and activity in
peripheral blood (Bowen et al., 2009) have been attributed both to
lack of effect and increased toxicity of gemcitabine (Sugiyama et al.,
2007; Ciccolini et al., 2010; Gusella et al., 2011). In PDAC tumor tissue,
it has been found that CDA mRNA expression is higher compared with
healthy tissues (Mameri et al., 2017). Bacteria and cells such as
macrophages in the tumor microenvironment that express CDA
might contribute to gemcitabine resistance (Vande Voorde et al.,
2014; Weizman et al., 2014; Geller et al., 2017; Hessmann et al.,
2018). However, the impact of intracellular CDA on gemcitabine
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metabolism in cancer cells is less studied (Morita et al., 2003; Vande
Voorde et al., 2014).
Mameri et al. (2017) restored the expression of CDA in two a priori
CDA-deficient cancer cell lines and showed that survival of these cells
was higher than that of their CDA-deficient counterparts following
in vitro incubation with gemcitabine. Indeed, similar results have also
been achieved by others, indicating a reciprocal relationship between
intracellular CDA activity and cellular gemcitabine sensitivity (Morita
et al., 2003; Giovannetti et al., 2007; Yoshida et al., 2010; Peters et al.,
2019). Thus, intracellular conversion of gemcitabine to dFdU is likely to
be a mechanism contributing to gemcitabine resistance in this setting
(Bardenheuer et al., 2005; Giovannetti et al., 2007; Ohmine et al., 2012;
Vande Voorde et al., 2014; Mameri et al., 2017; Tibaldi et al., 2018).
In this study, we hypothesized that CDA plays a regulatory role in
intracellular gemcitabine activation in PDAC cells. To test the
hypothesis, we assessed intracellular and extracellular concentrations
of gemcitabine and metabolites after exposure to gemcitabine with
and without the use of the CDA inhibitor tetrahydrouridine (THU). We
also determined basal mRNA and protein expression profiles of CDA
and other main proteins involved in the transport and metabolism of
gemcitabine.
Materials and Methods
Chemicals, Reagents, and Consumables. Unless otherwise stated, chemicals
and reagents were purchased fromMerck KGaA (Darmstadt, Germany) and were
of analytical grade. Horse serum and sodium pyruvate were bought from Thermo
Fisher Scientific (Oslo, Norway), culture flasks and cryotubes from VWR (Oslo,
Norway), centrifuge tubes from Sarstedt (Oslo, Norway), and THU from AH
diagnostics (Oslo, Norway). All other reagents and equipment used for liquid
chromatography tandem mass spectrometry methods have been described
previously (Bjånes et al., 2015; Kamceva et al., 2015).
Cell Culture. Three human PDAC cell lines, BxPC-3, MIA PaCa-2, and
PANC-1, authenticated and generously provided by Prof. Anders Molven
(University of Bergen), were cultured in 75-cm2 flasks in a humidified atmosphere
with 5% CO2 at 37C and subcultured twice weekly. BxPC-3 cells were cultured
in RPMI 1640 medium. MIA PaCa-2 and PANC-1 were cultured in Dulbecco’s
modified Eagle’s medium D5671 (DMEM). All media were supplemented with
10% FBS, 4 mM sodium pyruvate, and 2 mML-glutamine. The medium used for
MIA PaCa-2 was additionally supplied with horse serum (2.5%) as recommended
by the manufacturer. No antibiotics were used. Mycoplasma tests performed on
a regular basis were negative.
Gemcitabine Incubation. Cell-free media (RPMI, DMEM, and DMEM with
horse serum) were spiked with 10 or 100 mM gemcitabine. Resulting spiked
medium samples were aliquoted and stored in 1.5-ml Eppendorf tubes at 4C,
room temperature, and 37C for up to 7 days and subsequently stored at 280C
until the entire batchwas analyzed concurrently. The concentration ratios of dFdU
over the sum of gemcitabine and dFdU in each sample, dFdU/(gemcitabine 1
dFdU) (%), was used as an indicator of CDA activity.
PDAC cell lines (0.25–0.4  106 cells per well in 2 ml culture medium) were
seeded in 6-well plates 48 hours prior to gemcitabine incubation. Culture media
was removed and replaced with freshly prepared drug-supplemented media at
initiation of the experiments. The cells were incubated in quadruplicate for: 1)
24 hours with 10 or 100 mM gemcitabine with or without 200 mM THU or 2)
60 minutes with 10 or 100 mM gemcitabine with or without 200 mM THU. The
two different durations of gemcitabine incubation were chosen based on: 1) that
24 hours is within a typical range applied in in vitro cytotoxicity experiments
(Giovannetti et al., 2007; Yoshida et al., 2010; Mameri et al., 2017) and 2) that
60 minutes in vitro incubation reflects a comparable exposure to in vivo
gemcitabine treatment (Gusella et al., 2011). Following gemcitabine incubation,
media was collected, transferred to cryotubes, and stored at 280C until
quantification of extracellular gemcitabine and dFdU. Wells were rinsed twice
with PBS, and cells were subsequently trypsinized for 5–8minutes, harvested, and
gently resuspended in cold culture medium. Manual cell counting was performed
on a representative sample of the suspension. Cell suspensions were centrifuged
for 5 minutes. Supernatant was discarded, and the cell pellets were dissolved in
cold 60% methanol, transferred to cryotubes, vortexed for 20 seconds, and snap
frozen on liquid nitrogen. All samples were stored at 280C until quantification
of intracellular dFdCTP.
Gemcitabine and Metabolite Quantification. Quantification of gemcitabine
and its metabolites was performed using an Agilent 1200 series HPLC
system (Agilent Technologies, Waldbronn, Germany) for chromatographic
separation and an Agilent 6410 triple-quad mass spectrometer for mass detection.
Gemcitabine and dFdU in culture media samples were quantified as previously
described (Bjånes et al., 2015) and optimized with lower limits of quantitation of
0.1mMfor both gemcitabine and dFdU. dFdCTPwas analyzed in cell lysates with
a modified version of our previously published method (Kamceva et al., 2015).
Modification consisted of shorter analysis time and the mass spectrometer
operating in positive ionization mode because we were only interested in
quantification of dFdCTP and not in the endogenous nucleosides that eluted
later. dCTP was used as internal standard because of its similar structure and
retention time with dFdCTP. Concentrations above the lower limit of quantitation
of 0.05 mM were normalized to the cell count in each sample and expressed as
picomoles per 106 cells (abbreviated to pmol/106 throughout the manuscript).
mRNA and Protein Expression. Extraction of mRNAwas performed on cell
pellets from each cell line in quadruplicate by using the Qiagen column extraction
kit. Two micrograms of mRNA was used for reverse transcription with Moloney
Murine Leukemia Virus reverse transcriptase (InVitrogen). cDNA was diluted,
and relative gene expression was determined by PCR in a final volume of 6.67 ml
with Takyon NoRox SYBR MasterMix blue dTTP (Eurogentec). Triplicate runs
were performed on a Lightcycler (LC480; Roche Life Science). Relative
quantification was performed by the DDCTmethod using 28S mRNA expression
as a housekeeping gene and mean CT values as reference. Primers used for each
gene are given in Supplemental Table 1A.
Total proteinswere extracted using cold buffer (20mMTris-HCl pH6.8, 1mM
MgCl2, 2 mM EGTA, 0.5% NP40, and phosphatase inhibitor cocktails) with
60 minutes incubation on ice followed by centrifugation (15 minutes, 12,000g,
4C). Proteins were separated by SDS-PAGE and transferred onto polyvinylidene
difluoride membranes using the iBlot system (Life Technologies). Membranes
were incubated with specific antibodies, as shown in Supplemental Table 1B.
Protein expression was visualized using the Odyssey infrared system (LI-COR
Biosciences). Protein bands were quantified using the Odyssey system,
subtracting background noise from a similarly sized area just below the band,
and presented as ratio of the expression of proteins of interest versus beta-
actin expression.
Data Processing and Statistics. Quantitative data were analyzed with SPSS
Statistics 24.0 (IBM Inc., Armon, NY) andGraphPad Prism 8 (SanDiego, CA) for
Windows. Results were expressed as means 6 S.D. or as concentration ratios
between analytes (%). A two-sided Student’s t test was used to compare results in
individual cell lines under different experimental conditions. One-way ANOVA
with Bonferroni post hoc test was used to compare results in different cell lines. A
P value of less than 0.05 was considered significant.
Results
CDA Activity in Cell-Free Culture Media. We investigated
whether cell-free culture media had any CDA activity, which would
be of importance in the subsequent interpretation of data from cell lines
incubated with gemcitabine. We found CDA activity only in DMEM
supplemented with horse serum used for culturing MIA PaCa-2 cells.
Within the maximum duration of our cell experiments (24 hours), the
highest dFdU/(gemcitabine 1 dFdU) ratio at both gemcitabine concen-
trations was 6.3% at 37C (Supplemental Fig. 1). No CDA activity was
found in either RPMI or DMEM media without horse serum.
Accumulation of Inactive Gemcitabine Metabolite in Culture
Media. To quantify inactivation of gemcitabine in PDAC cells, we
measured extracellular dFdU concentrations after incubation with 10
and 100 mM gemcitabine for 60 minutes or 24 hours, with or without
inhibition of CDA. After 24 hours incubation of BxPC-3, MIA PaCa-2,
and PANC-1 with 100 mM gemcitabine, mean dFdU concentrations
were 86.3, 23.5, and 7.3 mM, respectively (Fig. 1A). After
60 minutes incubation with 100 mM gemcitabine, the corresponding












dFdU concentrations were 17.7, 3.7, and 0.2 mM (Supplemental
Fig. 2A). The percentage conversion of gemcitabine to dFdU was
similar when cells had been incubated with 10 mM gemcitabine both
after 60 minutes and 24 hours. After coincubation with gemcitabine
and THU, dFdU was low or undetectable in medium from all three
cell lines both after 60 minutes and 24 hours.
Intracellular Accumulation of Active Gemcitabine Metabolite.
After 24 hours incubation of BxPC-3, MIA PaCa-2, and PANC-1 with
10 mM gemcitabine, mean dFdCTP concentrations were 210, 1466, and
955 pmol/106, respectively (Fig. 1B). After 24 hours incubation with
100 mM gemcitabine, dFdCTP concentrations in BxPC-3 were signif-
icantly higher (851 pmol/106; P, 0.001) than with 10 mM gemcitabine
incubation. In MIA PaCa-2, dFdCTP concentrations were not
significantly different between the two gemcitabine concentrations
(P 5 0.12), whereas in PANC-1, they were significantly lower at
100 mM gemcitabine (662 pmol/106; P , 0.05). CDA inhibition
resulted in significantly higher dFdCTP concentrations in BxPC-3,
with mean concentrations of 1370 (P , 0.01) and 1368 pmol/106
(P , 0.05) at 10 and 100 mM gemcitabine, respectively. In MIA
PaCa-2 or PANC-1, dFdCTP concentrations were not significantly
different with versus without CDA inhibition.
After 60 minutes incubation with 10 mM gemcitabine, mean dFdCTP
concentrations were 92, 80, and 110 pmol/106 in BxPC-3, MIA PaCa-2,
and PANC-1, respectively. Sixty minutes incubation with 100 mM
gemcitabine did not result in significantly higher dFdCTP concentra-
tions in any of the three cell lines. Also, CDA inhibition had no effect on
dFdCTP concentrations at both gemcitabine concentrations under these
experimental conditions (Supplemental Fig. 2B).
Basal mRNA and Protein Expression. We assessed basal mRNA
and protein expression of selected transporters and enzymes involved in
gemcitabine uptake, metabolism, and activity in gemcitabine-untreated
cell lines. Relative expression of mRNA and proteins are given in Fig. 2,
respectively. Original Western blots can be seen in Supplemental Fig. 3.
CDA showed highest mRNA and protein expression in BxPC-3. Lower
CDAmRNA expression (Fig. 2A) and zero protein expression (Fig. 2B)
was detected in both MIA PaCa-2 and PANC-1. The majority of the
other transporters and enzymes revealed highest mRNA and protein
expressions in PANC-1.
Discussion
Our overall finding was that intracellular cytidine deaminase plays
a regulatory role for gemcitabine activation in PDAC cells, hence
confirming our hypothesis.
Gemcitabine Inactivation. Almost all gemcitabine added to the
culture medium was converted to dFdU during 24 hours gemcitabine
incubation of BxPC-3, highlighting the extensive CDA activity in this
cell line. A comparable extent of gemcitabine conversion was reported
by Bowen et al. (2009) in ex vivo whole blood from healthy volunteers,
as 50% after 5 hours incubation and close to 100% after 24 hours. In
accordance with other publications (Funamizu et al., 2012a,b), we
also found that CDA displayed the highest mRNA (Fig. 2A) and
protein expression (Fig. 2B) in BxPC-3 compared with MIA PaCa-2
and PANC-1.
Based on the pre-experimental stability assessments in cell-free
culture media, all dFdU in BxPC-3 experiments was a result of cellular
uptake, intracellular conversion, and subsequent efflux into the culture
medium. In MIA PaCa-2 and PANC-1, respectively, the extent of
gemcitabine conversion to dFdU was 20%–30% and,10% of BxPC-3
(Fig. 1A). This indicated that CDA activities were lower in MIA PaCa-2
and PANC-1. Gemcitabine was also to some extent converted to dFdU
in the medium used for culturing MIA PaCa-2 (Supplemental Fig. 1).
However, the conversion in cell-free medium only accounted for
20%–30% of the total amount found after 24 hours gemcitabine
incubation of MIA PaCa-2 cells (Fig. 1A). The finding of no detectable
CDA protein expression (Fig. 2B) in MIA PaCa-2 and PANC-1 did not
fit with the appearance of dFdU following 24 hours gemcitabine
incubation. These inconsistencies could preferably be explained by lack
of sensitivity in the protein expression assay (Supplemental Fig. 3)
because both cell lines expressed CDA mRNA (Fig. 2A). Moreover,
it has been suggested that transcriptional, posttranscriptional (Mameri
et al., 2017), and posttranslational (Frese et al., 2012) modulations could
blur the relationship between mRNA and protein expression and the
observed CDA phenotype.
In all cell lines, a long-lasting and strong inhibition of gemcitabine
inactivation was achieved with 200 mM THU even at the highest
gemcitabine concentrations and at both incubation durations. This is in
line with previous studies in human blood performed by our own group
(Bjånes et al., 2015) and other researchers (Bowen et al., 2009). dFdU
could otherwise be assumed to be derived from the deamination of
dFdCMP (Wong et al., 2009), but THU is not known to inhibit
gemcitabine-inactivating enzymes other than CDA (Heinemann and
Plunkett, 1989). The fact that coincubation of the cell lines with THU
inhibited the formation of dFdU effectively underscores that direct
gemcitabine deamination through CDA was the main source of dFdU in
our experiments.
Gemcitabine Activation. Without CDA inhibition, BxPC-3 accu-
mulated significantly less dFdCTP over 24 hours compared with the two
other cell lines (Fig. 1B). A probable explanation, in line with previous
theories (Riva et al., 1992; Bardenheuer et al., 2005), was that the supply
into the activation pathway was limited because of extensive conversion
of gemcitabine to dFdU (Fig. 1A). This notion was supported by the
observation that dFdCTP concentrations in BxPC-3 were significantly
higher when gemcitabine exposure was increased, either by increasing
gemcitabine concentrations from 10 to 100 mM (Fig. 1B) or by
inhibiting CDA (Fig. 1B). No increase in dFdCTP concentrations was
seen with increasing gemcitabine concentrations in MIA PaCa-2 or
PANC-1, although baseline CDA activities were low. The samewas true
in BxPC-3 when CDA was inhibited. These findings were consistent
with saturation kinetics of dCK, as previously described by others
(Grunewald et al., 1991; Wong et al., 2009).
Despite the distinct effects after 24 hours incubation in BxPC-3, CDA
inhibition had no effect on dFdCTP concentrations in any of the three
cell lines when incubated for 60 minutes (Supplemental Fig. 2B). These
findings could preferably be explained by sufficient concentrations of
gemcitabine still available for the activation pathway in all three cell
lines but with dCK operating close to its saturation limit. This view is
supported by the fact that the mean percentage gemcitabine remaining
in the medium after 60 minutes versus 24 hours incubation without
THUwas 77%versus,5% inBxPC-3, 92%versus 66% inMIAPaCa-2,
and .98% versus 80% in PANC-1.
Overall Perspective. Studies have highlighted the importance of
CDA with respect to in vivo gemcitabine systemic pharmacokinetics
(Sugiyama et al., 2007; Ciccolini et al., 2010; Gusella et al., 2011) and
in vitro drug sensitivity (Yoshida et al., 2010; Funamizu et al., 2012b;
Vande Voorde et al., 2014; Mameri et al., 2017), but the quantitative
aspects of intracellular gemcitabine metabolism in PDAC cells has not
previously been examined. We found that concentrations of both dFdU
and dFdCTP after incubation with gemcitabine varied considerably
between the PDAC cell lines, depending on CDA activity. As all three
cell lines in this study are frequently used in in vitro PDAC studies
(Funamizu et al., 2010, 2012a; Paproski et al., 2010; Mariglia et al.,
2018), the observed metabolic variability may be important to take
into account when interpreting results from gemcitabine incubation












experiments. Moreover, the quantitative contribution of intracellular
CDA in gemcitabine metabolism may provide a mechanistic expla-
nation by which manipulating CDA activity could modify cellu-
lar gemcitabine sensitivity, as demonstrated by Bardenheuer et al.
(2005) and Mameri et al. (2017).
By incubating the cell lines with gemcitabine with and without
THU, we demonstrated that an extensive CDA-mediated gemcitabine
conversion to dFdU in BxPC-3 was associated with less accumulation
of the active metabolite dFdCTP. This was evident after 24 hours
incubation but not after 60 minutes, indicating that a balanced
substrate supply to dCK was an important factor for the accumulation
of dFdCTP. In MIA PaCa-2 and PANC-1, no such effect of CDA
inhibition on the gemcitabine activation pathway was seen, which was
consistent with their a priori low CDA activities. This supports the
Fig. 1. Concentrations of gemcitabine metabolites following 24 hours incubation with 10 or 100 mM gemcitabine 6 200 mM tetrahydrouridine (THU), a cytidine deaminase
inhibitor. (A and B) show extracellular dFdU (micromolars) and intracellular dFdCTP (picomoles per 106), respectively. Insert in (A) shows data from 10 mM
gemcitabine incubations in greater detail, with a differently scaled y-axis. Data are displayed as means (n 5 4–8). Error bars excluded from view for clarity. Original
data are shown in Supplemental Table 2. *dFdCTP concentrations in PANC-1 incubated with 10 mM gemcitabine with or without THU are overlapping and
therefore appear as a single symbol.
Fig. 2. (A) Relative mRNA expression of selected proteins involved in the transport and metabolism of gemcitabine in BxPC-3, MIA PaCa-2, and PANC-1. Cytidine
deaminase is highlighted (red rectangle). Data are displayed as means of four independent samples studied in triplicate, and error bars are S.D. SLC28A1*: hCNT1,
concentrative nucleoside transporter 1; SLC29A1: hENT1, equlibrative nucleoside transporter 1; SLC29A2: CMPK1, uridine/cytosine monophosphate kinase; dCK,
deoxycytidine kinase; hENT2, equlibrative nucleoside transporter 2; NME2: CDA, cytidine deaminase; dCTD, deoxycytidine monophosphate deaminase; NdPK, nucleoside
diphosphate kinase; NT5C: cdN, cytosolic 59(39)-deoxyribonucleotidase; NT5C2: cN-II, cytosolic 59-nucleotidase II; NT5C3: cN-IIIA, cytosolic 59-nucleotidase III A;
NT5M: CTPS1*, cytidine triphosphate synthase 1; DCTPP1, deoxycytidine triphosphate pyrophosphatase 1; mdN, mitochondrial 59(39)-deoxyribonucleotidase; POLA1,
deoxyribonucleic acid polymerase alpha; RRM1, large subunit of ribonucleotide reductase; RRM2, small subunit of ribonucleotide reductase. mRNA expression of
SLC28A1 not detectable. (B) Relative protein expression of selected proteins involved in the transport and metabolism of gemcitabine in BxPC-3, MIA PaCa-2, and
PANC-1. Cytidine deaminase highlighted (red rectangle). Data are displayed as means of three independent samples, and error bars are S.D. Raw data are available in
Supplemental Fig. 3. cN-II, cytosolic 59-nucleotidase II (NT5C2); cN-IIIA, cytosolic 59-nucleotidase III A (NT5C3); dCK, deoxycytidine kinase; RRM1, large subunit of
ribonucleotide reductase; RRM2, small subunit of ribonucleotide reductase. *Antibodies against transporter proteins (hCNT and hENT) not available.












idea that CDA activity may be a predictor for gemcitabine activation
by regulating intracellular gemcitabine metabolism (Bardenheuer
et al., 2005; Tibaldi et al., 2018). The observation that MIA PaCa-2
cells produced both more dFdU and dFdCTP than PANC-1 cells
following 24 hours gemcitabine incubation could be explained by
the higher expression of 59-nucleotidases in PANC-1 (Fig. 2B),
particularly cN-IIIA. Indeed, this enzyme has been suggested to
dephosphorylate dFdCMP and thus oppose the accumulation of
dFdCTP (Li et al., 2008; Aksoy et al., 2009). To decipher the exact
mechanisms of these differences and the involvement of each of the
other proteins shown in Fig. 2, it would be necessary to develop
additional tools (protein-deficient cells, specific inhibitors, etc.) that
are outside the scope of this work.
Direct quantification of gemcitabine and its metabolites (Fig. 1),
combined with CDA inhibition, provided insight into differential CDA
activities that could not be revealed by expression analyses alone
(Fig. 2). In a recent commentary by Peters et al. (2019), phenotyping
with cytidine or gemcitabine was also recommended over genotyping
for pretreatment assessment of in vivo CDA activity in patients. Hodge
et al. (2011a,b) also demonstrated the value of applying different drug
concentrations and duration of incubations, combined with enzyme
inhibition, when studying cellular regulation of gemcitabine transport
(Hodge et al., 2011b) and metabolic (Hodge et al., 2011a) pathways.
In our experiments, we measured the free dFdCTP concentrations and
did not have a measure of the total intracellular amount comprising both
free and DNA-bound gemcitabine that might correlate better with
cytotoxicity (Gandhi et al., 1991). Indeed, using the AnnexinV-PI assay,
no additional effect of CDA inhibition was observed in any of the cell
lines (Supplemental Fig. 4), underscoring that free dFdCTP is not the
only determinant of gemcitabine efficacy. The ratio between free and
total dFdCTP is expected to change over time during and after
gemcitabine incubation, and cell lines might also behave differently
based on intracellular enzyme expressions, illustrated by our own results
in Fig. 2. Based on in silico simulations, Battaglia and Parker (2011)
suggested that the rate of DNA incorporation in general is a slow process
compared with the production rate of dFdCTP. Hence, quantification of
free dFdCTP could therefore be a better measure of cellular uptake and
metabolism of gemcitabine following 60 minutes incubation compared
with 24 hours incubation. Incubation for 60 minutes with 10–100 mM
gemcitabine in vitro might also more accurately represent the in vivo
drug exposure during and after clinically applied 30-minute gemcitabine
infusions of 1000 mg/m2, with a comparable concentration-time product
(area under the curve) of 41 6 12 mM*h (Gusella et al., 2011). We
calculated that 60 minutes or 24 hours in vitro incubation with 10 mM
gemcitabine renders areas under the curve of 10 or 240 mM*h,
respectively.
In general, data from in vitro experiments should be interpreted
with caution in terms of in vivo relevance. However, our finding
that increased gemcitabine exposure does not necessarily lead to an
increase in the intracellular active metabolite concentrations are
in line with observations from in vivo studies, as illustrated by
Hessmann et al. (2018).
Conclusion
Our findings reveal quantitative aspects of gemcitabine intracellular
metabolism in PDAC cell lines. The data support the notion that high
CDA activity limits intracellular dFdCTP accumulation. However, low
CDA activity may not necessarily result in increased dFdCTP accumu-
lation and decreased cell viability. Both CDA activity and the cellular
ability to synthesize active metabolites should be taken into consider-
ation in future studies of gemcitabine delivery to pancreatic cancer cells.
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Forward primer (5’-3’) Reverse primer (5’-3’) 
   
RPS28 CGATCCATCATCCGCAATG AGCCAAGCTCAGCGCAAC 
SLC28A1 TCTGTGGATTTGCCAATTTCAG CGGAGCACTATCTGGGAGAAGT 
SLC29A1 GCTGGGTCTGACCGTCGTAT CGTTACAGGGTGCATGATGG 
SLC29A2 ATGAGAACGGGATTCCCAGTAG GCTCTGATTCCGGCTCCTT 
DCK AAACCTGAACGATGGTCTTTTACC CTTTGAGCTTGCCATTCAGAGA 
CMPK1 GGGCATATTCTTTGCTTCCA TGCATTTCAAGGTTCCACTG 
NME2 ATGCAGTGCGGCCTGGTGGG GACCCAGTCATGAGCACAAGAC 
CDA GAGCTGCAATCGTGTCTGG CAGAGCAGCGGGAAACAG 
DCTD GTCGCCTTGTTCCCTTGTAA TCTTGCTGCACTTCGGTATG 
NT5C GGACACGCAGGTCTTCATCTG GCGGTACTTCTCACCCACACA 
NT5C2 ACCTGCTGTATTACCCTTTCAGCTA GCTCCACCGTTGATTCATGA 
NT5C3A AATCGGCGATGTACTAGAG CATCTGCCATTCTTAAGTCTC 
NT5M CATCAGCATTTGGGAGTCAA CGACACAATCTGCTCCAGAA 
DCTPP1 AAATGGACATCAACCGGCGA AGTCACAGGGAATGTCCGCA 
CTPS1 GTGGCGAAATACACCGAGTT TCCTCGAACACCAAATCCTC 
POLA1 AGCTTGACCTGATTGCTGTC ATGACGGGACAAAGACAAGG 
RRM1 GCAGCTGAGAGAGGTGCTTT CAGGATCCACACATCAGACA 
RRM2 GAGTTCCTCACTGAGGCC TTAGAAGTCAGCATCCAAG 
   
   
RPS28; Ribosomal protein S 28; SLC28A1*: Concentrative nucleoside transporter 1 (hCNT1); SLC29A1: 
Equlibrative nucleoside transporter 1 (hENT1); SLC29A2: Equlibrative nucleoside transporter 2 (hENT2); 
dCK: deoxycytidine kinase; CMPK1: uridine/cytosine monophosphate kinase; NME2: nucleoside 
diphosphate kinase (NdPK); CDA: Cytidine deaminase; dCTD: deoxycytidine monophosphate deaminase; 
NT5C: cytosolic 5’(3’)-deoxyribonucleotidase (cdN); NT5C2: cytosolic 5’-nucleotidase II (cN-II); NT5C3: 
cytosolic 5’-nucleotidase III A (cN-IIIA); NT5M: mitochondrial 5’(3’)-deoxyribonucleotidase (mdN); RRM1: 
Large subunit of ribonucleotide reductase; RRM2: Small subunit of ribonucleotide reductase; DCTPP1: 
deoxycytidine triphosphate pyrophosphatase 1; CTPS1*: cytidine triphosphate synthase 1; POLA1: 
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CDA -/ab56053 1/500 Primary Rabbit Abcam 
cN-II 3C1/H00022978-M02 1/500 Primary Mouse Abnova 
cN-IIIA -/ARP32185 1/1000 Primary Rabbit Aviva Systems Biology 
dCK -/ab96599 1/2000 Primary Rabbit Abcam 
RRM1 -/sc11733 1/1000 Primary Goat Santa Cruz Biotechnology 
RRM2 -/sc10846 1/1000 Primary Goat Santa Cruz Biotechnology 
Beta-actin AC-15/A5441 1/5000 Primary Mouse Sigma 
      
Anti-murine -/926-32210 1/5000 Secondary Goat LI-COR Bioscience 
Anti-rabbit -/926-68171 1/5000 Secondary Goat LI-COR Bioscience 
Anti-goat -/926-32214 1/5000 Secondary Donkey LI-COR Bioscience 
   
 
CDA: Cytidine deaminase; cN-II: cytosolic 5’-nucleotidase II (NT5C2); cN-IIIA: cytosolic 5’-nucleotidase III A 
(NT5C3); dCK: deoxycytidine kinase; RRM1: Large subunit of ribonucleotide reductase; RRM2: Small subunit 
of ribonucleotide reductase 
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Supplemental table 2. Extracellular dFdU and intracellular dFdCTP concentrations 
following 24 hours gemcitabine (10 or 100 µM) incubation with or without 200 µM 
tetrahydrouridine. Data displayed in Figure 1A and 1B.  
Cell line 









      
  10 µM  10.5* 1.1  209.6 29.5 
  10 µM + THU  0.6* 0.05  1370.0 182.4 
  100 µM  86.3 4.1  850.5 127.1 
  100 µM + THU  1.5 0.02  1368.5 200.5 
 
MIA PaCa-2       
  10 µM  3.4* 0.8  1465.5 247.6 
  10 µM + THU  n.d. n.d.  1420.4 95.7 
  100 µM  23.5* 7.1  1242.2* 197.0 
  100 µM + THU  0.8 0.2  1187.7* 203.6 
 
PANC-1       
  10 µM  1.1 0.0  954.7 224.7 
  10 µM + THU  0.2 0.0  950.9 66.8 
  100 µM  7.3 0.7  662.5 77.2 
  100 µM + THU  0.2 0.05  600.7 77.4 
       
n = 4-8 per experimental condition; * experiments with n=8; n.d.: not detectable; 
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Supplemental Figure 1. Stability of 10 µM gemcitabine (dFdC) in Dulbecco’s modified 
Eagles medium with horse serum at 4 °C, room temperature (RT) and 37 °C. dFdU 
concentrations relative to the sum of dFdC and dFdU concentrations 
([dFdU]/([dFdC]+[dFdU]), %), was used as a measure of CDA-activity. No CDA activity was 
found in either of the two other culture media; RPMI and DMEM. 
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Supplemental Figure 2. Concentrations of gemcitabine metabolites following 60 minutes 
incubation with 10 or 100 µM gemcitabine ± 200 µM tetrahydrouridine (THU), a cytidine 
deaminase inhibitor. A and B show extracellular dFdU* (µM) and intracellular dFdCTP 
(pmol/106), respectively. Data are displayed as means (n = 4 – 8). Error bars excluded from 
view for clarity.  
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Supplemental Figure 3. Western blots of protein expression of selected proteins involved in 
the transport* and metabolism of gemcitabine in BxPC-3, MIA PaCa-2 and PANC-1. 
Brackets indicate the individual analytical runs, with each beta-actin control included. 
CDA: Cytidine deaminase; cN-II: cytosolic 5’-nucleotidase II (NT5C2); cN-IIIA: cytosolic 5’-nucleotidase IIIA 
(NT5C3); dCK: deoxycytidine kinase; RRM1: Large subunit of ribonucleotide reductase; RRM2: Small subunit of 
ribonucleotide reductase 
*Antibodies against transporter proteins (hCNT and hENT) not available 
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Supplemental Figure 4. Viability of BxPC-3 (high CDA expression) and PANC-1 (low CDA 
expression) following 60 minutes or 24 hours incubation with 10 µM gemcitabine and/or 200 
µM tetrahydrouridine. THU: Tetrahydrouridine 200 µM; “Gem”: Gemcitabine 10 µM 
 
Cells (100,000 per well) were seeded in 24-well plates in 1 mL complete media and left to 
attach before adding the various compounds. Cells were incubated with 10 µM gemcitabine 
and/or 200 µM THU for 60 minutes or 24 hours. Media was changed and cells were 
incubated for another 47 or 24 hours (total incubation 48 hours). Unexposed cells were used 
as controls. After harvesting by trypsinisation and centrifugation, cells were labelled with 
AnnexinV-Fluos Staining kit (Roche) and AnnexinV and PI staining of cells was determined 
on flow cytometry (Fortessa, BD Biosciences) as indicated in manufactures’ instructions, and 
percentage alive cells were used as a measure of drug efficacy. Graph show mean values of 
four independent experiments performed in duplicate, and error bars are standard deviations.  
